Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)

PHASE3TerminatedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

March 18, 2021

Primary Completion Date

January 30, 2024

Study Completion Date

January 30, 2024

Conditions
BK Virus InfectionHemorrhagic Cystitis
Interventions
BIOLOGICAL

Posoleucel (ALVR105)

Administered as 2-4 milliliter infusion, visually identical to placebo

BIOLOGICAL

Placebo

Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)

Trial Locations (56)

14263

Roswell Park Comprehensive Cancer Center, Buffalo

19104

Children's Hospital of Philadelphia (CHOP), Philadelphia

20010

Children's National Medical Center, Washington D.C.

21287

Johns Hopkins Medicine, Baltimore

23284

Virginia Commonwealth University, Richmond

30342

Northside Hospital, Atlanta

33136

University of Miami, Miami

33612

Moffitt, Tampa

43210

Ohio State University Medical Center (OSUMC), Columbus

44106

University Hospitals Cleveland Medical Center, Cleveland

53226

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee

55455

University of Minnesota, Minneapolis

60611

Northwestern Memorial Hospital, Chicago

64108

Children's Mercy Hospital - Kansas City, Kansas City

66160

University of Kansas Cancer Center, Kansas City

68198

University of Nebraska Medical Center, Omaha

75390

The University of Texas Southwestern Medical Center, Dallas

90027

Children's Hospital of Los Angeles, Los Angeles

91010

City of Hope National Medical Center, Duarte

97239

Oregon Health & Science University, Portland

98109

Fred Hutchinson Cancer Research Center, Seattle

06520

Yale University School of Medicine - Yale Cancer Center, New Haven

02215

Dana-Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

07601

Hackensack University Medical Center, Hackensack

Unknown

CHU de Lille - Hopital Claude Huriez, Lille

CHU de Nantes - Hôtel-Dieu, Nantes

AP-HP Hopital Saint-Louis, Paris

HCL Centre Hospitalier Lyon Sud, Pierre-Bénite

IUCT-Oncopole, Toulouse

Azienda Ospedaliero-Universitaria Careggi, Florence

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan

IRCCS Ospedale San Raffaele, Milan

Ospedale Pediatrico Bambino Gesù, Roma

Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Rome

Istituto Clinico Humanitas, Rozzano

Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento, Verona

Chonnam National University Hwasun Hospital, Jeongnam

Asan Medical Center, Seoul

Pusan National University Hospital, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul

Severance Hospital, Yonsei University Health System, Seoul

Hospital Clinic Barcelona, Barcelona

Hospital Universitario La Paz, Madrid

Hospital Regional Universitario de Malaga, Málaga

Hospital Universitari i Politecnic La Fe, Valencia

Karolinska University Hospital, Stockholm

University Hospitals Bristol NHS Foundation Trust, Bristol

Queen Elizabeth University Hospital - Glasgow, Glasgow

Great Ormond Street Hospital for Children, London

Hammersmith Hospital, London

The Royal Marsden NHS Foundation Trust, London

University College London Hospital, London

Nottingham University Hospitals, Nottingham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AlloVir

INDUSTRY

NCT04390113 - Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC) | Biotech Hunter | Biotech Hunter